NCT01664845

Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Kaohsiung Veterans General Hospital. · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to investigate the treatment response of metformin, Peg-IFN and ribavirin combination therapy for chronic hepatitis C virus (HCV).

Detailed description

Current standard of treatment for HCV with pegylated interferon(Peg-IFN)-alpha and ribavirin can achieve sustained virological response (SVR) in only 60-90% of patients. Insulin resistance is an important factor of non-response to combination therapy. Metformin is a insulin sensitizer and can effectively reduce insulin resistance. The aim of the study is to investigate the treatment response of metformin, Peg-IFN and ribavirin combination therapy for chronic HCV.

Conditions

• Chronic Hepatitis c
• Insulin Resistance

Interventions

Type	Name	Description
DRUG	metformin	metformin 500mg tid
DRUG	pegylated-IFN	pegasys 180 mcg qw
DRUG	ribavirin	ribavirin 800-1200 mg qd according to BW

Timeline

• Start date: 2012-08-01
• Primary completion: 2014-08-01
• Completion: 2014-08-01
• First posted: 2012-08-14
• Last updated: 2012-08-14

Locations

1 site across 1 country: Taiwan